Morgan Stanley’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

Morgan Stanley’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-60,740	Closed	-$619K	–	8043
2023 Q3	$619K	Sell	60,740 -14,045	-19%	-$107K	﹤0.01%	5070
2023 Q2	$351K	Buy	74,785 +30,426	+69%	+$140K	﹤0.01%	5390
2023 Q1	$205K	Buy	44,359 +25,533	+136%	+$112K	﹤0.01%	5700
2022 Q4	$68.3K	Sell	18,826 -11,452	-38%	-$50.8K	﹤0.01%	6150
2022 Q3	$144K	Sell	30,278 -24,070	-44%	-$121K	﹤0.01%	5896
2022 Q2	$263K	Buy	54,348 +42,162	+346%	+$256K	﹤0.01%	5759
2022 Q1	$77K	Sell	12,186 -4,908	-29%	-$26.4K	﹤0.01%	6476
2021 Q4	$107K	Buy	+17,094	New	+$134K	﹤0.01%	6404

Morgan Stanley's THRN Position: Q4 2023 in Review

Morgan Stanley sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 60,740 shares — an estimated $619K sold.

Morgan Stanley first reported a position in THRN in Q4 2021 and held it in 8 quarters. The position peaked at $619K in Q3 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

Morgan Stanley reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Morgan Stanley sold 60,740 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $619K.
Morgan Stanley first reported a position in Thorne Healthtech, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Morgan Stanley's Thorne Healthtech, Inc. Common Stock position peaked at $619K in Q3 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.